Mark J. Suto, Ph.D., was named vice president of Drug Discovery in August 2011. He and his team focus on basic research and target identification and lead discovery and optimization of new therapies for cancer, infectious diseases, and neurological diseases and disorders.
Suto served as vice president of chemical and pharmaceutical sciences at Icagen Inc. from April 2004 until he joined SR. From 2003-2004, he was executive vice president and chief scientific officer of Neurion Pharmaceuticals Inc., a California biotech company. From 1999-2002, Suto held senior management roles at DuPont Pharmaceuticals (acquired by Bristol-Myers Squibb Company) and Deltagen Research Laboratories, a subsidiary of Deltagen Inc.
Prior to DuPont Pharmaceuticals, Suto held management positions at CombiChem Inc. and Signal Pharmaceuticals Inc., and from 1982-1993, he held positions of increasing responsibility in the chemistry department at Parke-Davis Pharmaceutical Research in Ann Arbor, Michigan. He received his doctorate and his bachelor’s degree in medicinal chemistry from the State University of New York at Buffalo.
Suto is a member of the American Chemical Society and has served on the editorial boards for several scientific journals, including Combinatorial Chemistry and High Throughput Screening, Investigational Drugs Section Editor, Expert Opinion in Drug Discovery, and Expert Opinion on Therapeutic Patents. He currently holds 43 U.S. patents and has five additional U.S. patents pending.